The prevalence of early-stage non-small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy.
N on-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer, the leading cause of death from cancer in the United States and worldwide. 1 Biomarkers that can reliably estimate disease prognosis and patient survival would have tremendous value in guiding the management of lung cancer. 2 For example, most patients with stage I NSCLC currently do not receive adjuvant systemic treatment after local therapy because several large randomized studies [3] [4] [5] have failed to show a survival benefit among unselected patients, for whom the toxic effects associated with chemotherapy may outweigh the potential benefit for many patients. Thus, identification of the subset of patients at highest risk for recurrence and death who have the greatest need for additional systemic therapy is needed.
A number of studies have proposed gene expressionbased signatures for survival stratification in patients with NSCLC. [6] [7] [8] [9] [10] Unfortunately, none has been incorporated into routine clinical practice owing to issues such as overfitting on small discovery data sets and lack of sufficient validation. 11 The availability of public, large-scale gene expression data sets brings the opportunity to identify potentially more reliable lung cancer biomarkers. 8, 12, 13 To use all this information effectively, however, the diversity of data also represents a daunting challenge. Traditional approaches using gene expression levels require appropriate normalization, which is a difficult task given the potential biological heterogeneity among data sets and technical biases across measurement platforms. 14 Instead, methods based on the relative ranking of gene expression levels eliminate the requirement for data preprocessing, such as scaling and normalization, and have been shown to produce robust results in various applications, including cancer classification.
15-17
Various components of the immune system have been shown to be a determining factor during cancer initiation and progression. 18, 19 Evading immune destruction has been recognized as an emerging hallmark of cancer. [20] [21] [22] [23] Recent immunotherapies targeting specific immune checkpoints such as programmed death 1 or programmed death ligand 1 have demonstrated a remarkable, durable response in NSCLC. 24, 25 Certain histopathologic patterns, such as intratumoral infiltration by cytotoxic lymphocytes, have also been associated with better prognoses in several cancer types, including NSCLC. [26] [27] [28] [29] [30] However, the molecular characteristics describing tumorimmune interaction remain to be comprehensively explored regarding their prognostic potential in NSCLC. [31] [32] [33] [34] In this study, we combined multiple gene expression data sets to develop and validate an individualized prognostic signature for nonsquamous NSCLC based on immune-related gene pairs (IRGPs). To leverage the complementary value of molecular and clinical characteristics, we integrated the immune signature with clinical factors to build a composite prognostic index, which allowed improved estimation of nonsquamous NSCLC prognosis.
Methods

Study Design and Patients
We retrospectively analyzed the gene expression profiles of frozen tumor tissue samples from 19 public NSCLC cohorts, including 18 microarray data sets and 1 RNA-Seq data set for The Cancer Genome Atlas (TCGA) lung adenocarcinoma cohort. Only patients with nonsquamous NSCLC with clinical annotation were included. 35, 36 We excluded patients who had a positive surgical margin or had received neoadjuvant therapy, adjuvant chemotherapy, or other pharmaceutical therapy owing to immune-modulating effects of some therapeutics.
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Overlapped patients (n = 19) between the Director's Challenge Consortium (DCC) and a data set in Gene Expression Omnibus (GSE14814) were removed from the DCC data set. Overall, we included 2414 patients in our study (eTable 1 in the Supplement). Details about sample preparation and RNA measurement can be found elsewhere. 7, 8, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Preprocessing of gene expression profiles can be found in the eMethods in the Supplement. This study of deidentified data was approved by the institutional review board of Stanford University, Palo Alto, California. Data were collected from July 22 to September 8, 2016. eFigure 1 in the Supplement shows the overall study design. We selected the 3 largest individual data sets for independent validation, namely, TCGA lung adenocarcinoma (TCGA), DCC, and GSE30219. The remaining 16 microarray data sets were merged into 1 meta-data set, which was randomly split approximately in half into meta-training and meta-testing data sets. Clinical and pathologic characteristics of patients in each data set are shown in eTable 2 in the Supplement.
Construction of an Individualized Prognostic Signature Based on IRGPs
We constructed a prognostic signature by focusing on immunerelated genes (IRGs), which were downloaded from the ImmPort database (https://immport.niaid.nih.gov). 53 A variety of IRGs were included, such as cytokines, cytokine receptors, and genes related to the T-cell receptor signaling pathway, B-cell antigen receptor signaling pathway, natural killer cell cytotoxicity, and antigen processing and presentation pathways. Immune-related genes measured by all platforms were selected. The gene expression level in a specific sample or profile underwent pairwise comparison to generate a score for each IRGP. An IRGP score of 1 was assigned if IRG 1 was less than IRG 2; otherwise the IRGP score was 0. This gene pair-based approach has an important advantage because the score is calculated based entirely on the gene expression profile
Key Points
Question Can molecular profiling of immune-related genes be used to estimate prognosis in early-stage nonsquamous non-small cell lung cancer?
Findings In this multiple-cohort study that analyzed frozen tumor tissue samples from 2414 patients, an immune signature of 25 gene pairs significantly stratified patients into low-vs high-risk groups for overall survival across and within subpopulations at various tumor stages (I, IA, IB, or II).
Meaning Dysregulated immune contexture may contribute to the survival differences among patients with nonsquamous non-small cell lung cancer.
of a tumor sample and can be used in an individualized manner without the need for normalization. Some IRGPs with constant values (0 or 1) in a particular platform or data set may be attributable to (1) platform-dependent preferential measurement, which can cause biases and may not be reproducible across platforms, and (2) biologically preferential transcription, which does not provide discriminative information about patient survivial. 54 Therefore, we removed
IRGPs with constant values in any individual data set of the meta-data set. Prognostic IRGPs were selected using the log-rank test to assess the association between each IRGP and patients' overall survival in the meta-training data set. Prognostic IRGPs with a familywise error rate less than 0.05 were candidates to build the IRGP index (IRGPI). To minimize the risk of overfitting, we applied a Cox proportional hazards regression model combined with the least absolute shrinkage and selection operator (glmnet, version 2.0-5). 55 The penalty parameter was estimated by 10-fold cross-validation in the meta-training data set at 1 SE beyond the minimum partial likelihood deviance.
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To separate patients into low-or high-risk groups, the optimal IRGPI cutoff was determined by a time-dependent receiver operating characteristic (ROC) curve (survivalROC, version 1.0.3) 56 at 5 years in the meta-training data set. We used the nearest neighbor estimation 57 method to estimate the ROC curve. The IRGPI corresponding to the shortest distance between the ROC curve and point representing the 100% truepositive rate and 0% false-positive rate was used as the cutoff value.
Validation of the IRGPI
The prognostic value of the IRGPI was assessed in patients with all stages of disease and in stage-specific groups (early stages [I/II], I, IA, IB, or II) in the meta-training, meta-testing, and independent validation cohorts in univariate analyses. We then combined IRGPI with available clinical and pathologic variables in multivariate analyses. Age, grade, and stage were treated as continuous variables. Grade was coded as well differentiated (0), moderately differentiated (1), or poorly differentiated (2). Stage IA was coded as 1; the range between IA and IB, as 1.5; IB, as 2; IIA, as 3; the range between IIA and IIB, as 3.5; IIB, as 4; IIIA, as 5; the range between IIIA and IIIB, as 5.5; IIIB, as 6; and IV, as 7. The prognostic accuracy of the biomarkers in continuous form was evaluated using the concordance index (C-index), which ranges from 0 to 1.0, with 0.5 indicating random estimation. We compared the prognostic accuracy of the IRGPI with 2 existing multigene signatures (eMethods in the Supplement) in terms of the C-index.
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Functional Annotation and Analysis 
Statistical Analysis
All statistical analyses were performed using R (version 3.3.1; https://www.r-project.org/). Univariate analysis of the association of IRGPI and other clinical pathologic factors with overall survival was evaluated using log-rank test. For factors significantly associated with overall survival in univariate analyses, multivariate analysis was performed with the Cox proportional hazards regression model. The C-index was calculated with survcomp (version 1.22.0) and compared with compareC (version 1.3.1) packages. 63 The RMS curve and RMS time ratio were estimated with survival (version 2.41-2) and survRM2 (version 1.0-2) packages. 62 Statistical significance was defined as P < .05 unless specified otherwise. Figure 1A and B). When further restricted to patients with stage IA or IB disease, the IRGPI could stratify patients into subgroups with significantly different prognoses in the meta-testing and/or independent validation cohorts (eFigure 5 in the Supplement). Similarly, a higher IR-GPI was correlated with significantly worse prognosis patients with stage II disease in meta-testing (HR, 1.73; 95% CI, and II nonsquamous NSCLC in 3 independent validation data sets. Hazard ratios (HRs) and 95% CIs are for high vs low immune risk. P values comparing risk groups were calculated with the log-rank test.
Results
Construction and Definition of the IRGPI
1.03-2.92; P = .037) and in independent validation cohorts (HR, 3.39; 95% CI, 1.80-6.37; P =5.53×10 -5 ) ( Figure 1C and D) and patients with more advanced stage III to IV disease (HR, 1.56; 95% CI, 1.14-2.15; P = .005) (eFigure 4F in the Supplement). Overall, the IRGPI appears to estimate overall survival indepently of stage in nonsquamous NSCLC ( Figure 2 ).
Functional Annotation of the IRGPI
Enrichment analysis of the 40 unique IRGs identified 6 overrepresented biological processes in gene ontology (eTable 5 in the Supplement). Most biological processes were chemotaxis. Chemotaxis of various immune infiltrates, such as neutrophils, monocytes, and macrophages, was observed. In the TCGA data set, we found that the percentages of necrosis and neutrophil infiltration were significantly different between IRGPI risk groups ( Figure 3) . The mean level of necrosis in the IRGPI high-risk group was 3-fold that in IRGPI low-risk group in the bottom (6.5% vs 2.1%; P =2 . 3 9×1 0 −6 ) and top (4.6% vs 1.5%; P =6 . 2 9×1 0 −13 ) sections. Patients with a higher IRGPI also had significantly higher neutrophil infiltration in their tumors in the bottom (4.8% vs 1.3%; P = .002) and top ( 4. 3%vs1. 6 %;P = .001) sections. However, no statistically significant difference in lymphocyte or monocyte infiltration was observed between the 2 IRGPI risk groups in the TCGA data set. included all 14 genes needed to construct the 14-gene biomarker. For both data sets, the IRGPI achieved a higher Cindex compared with the 14-gene biomarker (eFigure 6A in the Supplement). Of note, for patients with stages I to III disease in the TCGA data set, the C-index of the IRGPI was significantly different from random estimation (C-index, 0.62; 95% CI, 0.55-0.69; P < .001), whereas the 14-gene biomarker was not (C-index, 0.50; 95% CI, 0.44-0.56; P = .93). Similarly, in 3 of 4 data sets, the IRGPI showed a higher C-index than the CCP biomarker (eFigure 6B in the Supplement). Overall, the mean C-index weighted by cohort size was 0.64 for IRGPI vs 0.53 for the 14-gene biomarker and 0.61 for the CCP biomarker in respective comparisons. We used the same 1000 random splits of the meta-cohort to further assess the accuracy and variability of survival estimation for different biomarkers (eMethods in the Supplement). The IRGP-based models showed a higher median C-index of 0.65 and lower variation (SD, 0.015) in the metatesting cohorts compared with CCP and the 14-gene biomarker, with median (SD) C-indexes of 0.57 (0.020) and 0.56 (0.025), respectively.
Integrated Prognostic Index by Combining the IRGPI With Clinical Factors
In multivariate analysis (eTable 4 in the Supplement), age, stage and IRGPI were independent prognostic factors in at least 3 data sets, suggesting their complementary value. To further improve accuracy, we combined age, stage, and IRGPI score to fit a Cox proportional hazards regression model using the metatraining data set and derived an ICPI as (0.0265 × age) + (0.267 × stage) + (1.917 × IRGPI score). An optimal cutoff of 0.116 for stratifying patients was determined based on timedependent ROC curve analysis in the meta-training data set (eFigure 7A in the Supplement). Significantly improved estimation of survival was achieved by the continuous form of ICPI relative to IRGPI (mean C-index, 0.70 vs 0.63 in the validation data set; P < .005) (eFigure 7B in the Supplement and Figure 4) . Similar results were observed in binary form of the ICPI relative to the IRGPI (eFigure 8 and eTable 6 in the Supplement).
We also compared our ICPI with a commercialized clinicalmolecular composite biomarker mPS, which integrates stage with CCP score, in patients with early-stage disease (eMethods in the Supplement). Our ICPI achieved a higher accuracy of survival estimation in all validation data sets (mean C-index, 0.68 for ICPI vs 0.65 for mPS; eFigure 9 in the Supplement).
Discussion
Patients with early-stage NSCLC are at substantial risk for recurrence and death, even after complete surgical resection. The use of adjuvant therapy in early-stage, particularly stage I, NSCLC remains controversial, because previous randomized trials have not demonstrated a consistent survival benefit. Reliable prognostic biomarkers are critically needed to select patients who are at highest risk for recurrence and who might benefit from additional systemic therapy. Significant research on gene expression-based prognostic signatures [6] [7] [8] [9] [10] has led to recent commercialization of 2 biomarkers in lung adenocarcinoma, 6 ,9 but their accuracy of survival estimation remains limited. In this study, we developed a prognostic signature based on 25 immune-related gene pairs for nonsquamous NSCLC and validated it in multiple independent data sets across different platforms. Our prognostic immune signature can further stratify clinically defined groups of patients (eg, early-stage [I/II] and stages I, IA, IB, and II nonsquamous NSCLC) into subgroups with different survival outcomes. In benchmark comparisons, our signature achieved higher accuracy than 2 commercialized molecular biomarkers. We further leveraged the complementary value of molecular and clinical characteristics and showed that combining both could provide a more accurate estimation of overall survival in nonsquamous NSCLC.
To identify reliable biomarkers of nonsquamous NSCLC prognoses, we combined gene expression profiles from multiple data sets and used methods that are specifically designed to perform robustly given technical biases inherent across different platforms with microarray or RNA-Seq technologies.
65,66 Our prognostic signature is based on the relative ranking of gene expression values and only involves pairwise comparison within the gene expression profile of a sample, thus eliminating the need for data normalization. As such, our prognostic signature can serve as an individualized, single-sample estimate of survival of NSCLC and may be readily translated to clinical practice. Prognostic or predictive biomarkers related to the tumor immune microenvironment may hold great promise for identifying novel molecular targets and improving patient management in the era of immunotherapy. 2 Suzuki et al 67 discovered that stromal rather than tumor nest FoxP3:CD3 ratio and tumor expression level of certain cytokines (interleukin 12 receptor β2 and interleukin 7 receptor) were correlated with recurrence in stage I lung adenocarcinoma. Because gene expression profiles used in the present study were derived from a core sample of tumor tissue, we did not observe significant differences in lymphocyte infiltration between low-and highrisk IRGPI groups, which is consistent with the previous findings. Similarly, most genes contained in our immune signature were also cytokines and cytokine receptors, which play key roles in chemotaxis, angiogenesis, and inflammatory processes. 68 An increased inflammatory microenvironment has been shown to be a consistent component of neoplastic process and tumor progression. 
Limitations
Limitations of our study include its retrospective nature, although we tried to include as many data sets as possible for more rigorous validation of our biomarker. Similar to other studies, 76,77 gene expression signatures are subject to sampling bias caused by intratumor genetic heterogeneity. Although we excluded IRGPs with constant ordering to reduce certain cross-study batch effects, their complex nature implies that not all batch effects can be addressed, and some may remain. 14 Future studies will integrate diverse biological processes, which could provide a more complete molecular picture of the tumor.
Conclusions
The proposed immune-related gene pair-based signature is a promising prognostic biomarker in nonsquamous NSCLC, including early-stage disease. Prospective studies are needed to further validate its analytical accuracy for estimating prognoses and to test its clinical utility in individualized management of nonsquamous NSCLC. Gene symbols in TCGA dataset were also converted to Entrez IDs.
Assessing robustness of the 25 IRGPs and variability of prediction for different biomarkers
To evaluate the robustness of the selected 25 IRGPs, feature selection and model building were repeated 1000 times in different randomization of the meta-cohort. The same criteria described in Methods were used to find prognostic IRGPs and build IRGP-based models in each meta-training cohort. IRGPs that appeared in at least one prognostic model were considered. The frequencies of selected IRGPs were used to estimate a background distribution. The frequencies of the 25
IRGPs consisting of the IRGPI were examined and compared with the background distribution with Wilcoxon rank-sum test.
The C-index of IRGP-based prognostic biomarker, Cell Cycle Progression (CCP) score and the 14-gene biomarker was also calculated in 1000 randomization of the meta-testing cohort to estimate performance variations of each biomarker.
Implementations of CCP score and 14-gene biomarker were described below. The standard deviation of C-index was used to measure the variability of survival prediction for different biomarkers.
Comparison with commercialized lung biomarker:
The 14-gene biomarker consisting of 11 prognostic genes and 3 reference genes and the CCP biomarker consisting of 31 CCP genes were implemented. 4, 5 Briefly, for 14-gene biomarker, gene expression values of 11 prognostic genes were normalized by those of 3 reference genes and risk scores for each patient were calculated based on coefficients proposed by the original paper. 4 The construction of CCP biomarker was based on the pipeline designed for microarray data. 5 In short, Affymetrix datasets were normalized with Robust Multi-array Average (RMA) 6 method. For Illumina and Agilent datasets, GEO normalized datasets were used. The average expression value of 31 genes were used as the CCP score. 5 The performance of commercialized mPS 7 , which is an integration of CCP score with pathological staging was compared with our immune-clinical composite score ICPI in terms of C-index in the validation datasets.
eResults. Analysis and Robustness of IRGPs
Analysis of IRGPs with constant orderings
To further illustrate the possible causes of constant ordering, we categorized the total 126615 IRGPs with constant orderings into three groups based on measurement platforms and datasets. First, ~23% (29200) of IRGPs were consistently constant (all 0 or 1) in datasets only measured by a single platform (Affymetrix, Agilent or Illumina) and ~9% (11712) of IRGPs were consistently constant within one platform, but constant in the opposite direction in other platforms. These types of IRGPs, in our opinion, were caused by platform bias. Second, 58% (73805) IRGPs were consistently constant in datasets measured by at least two different platforms, which might be caused by biological preferential transcription. Third, the remaining 10%
(11898) IRGPs were inconsistently constant (1 for some datasets and 0 for others) between different datasets of the same microarray platform. The reasons for this may be various, and one possibility could be batch effects. 25 (3) 17 (2) 7 (2) 16 (8) 10 ( 8 (1) 
Robustness of 25 IRGPs in IRGPI
